Clinical Edge Journal Scan

Sonographic enthesitis associated with sonographic synovitis and tenosynovitis in PsA


 

Key clinical point : Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.

Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P = .004) and sonographic tenosynovitis (β 0.1; P = .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire ( P = .003), morning stiffness ( P = .002), and others.

Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202

Recommended Reading

Triglyceride-glucose index: A promising atherosclerotic marker in PsA
Psoriatic Arthritis ICYMI
Distinct clinical manifestations of PsA with axial involvement and axial spondyloarthritis with psoriasis
Psoriatic Arthritis ICYMI
Vitamin D deficiency associated with lowest retention rates of first bDMARD in PsA
Psoriatic Arthritis ICYMI
Age at disease onset influences disease characteristics in PsA
Psoriatic Arthritis ICYMI
Are patients with PsA more prone to cancer?
Psoriatic Arthritis ICYMI
Patients with PsA have lower vitamin D levels than general population, says meta-analysis
Psoriatic Arthritis ICYMI
Study identifies risk factors associated with PsA occurrence in patients with psoriasis
Psoriatic Arthritis ICYMI
Commentary: PsA development risks, and a new index, May 2023
Psoriatic Arthritis ICYMI
Secukinumab improves treatment outcomes and inhibits structural damage in PsA
Psoriatic Arthritis ICYMI
Enthesitis resolution similar with secukinumab and adalimumab in PsA
Psoriatic Arthritis ICYMI